Response to: 'Venous thromboembolic events in systemic vasculitis' by Novikov *et al*

We would like to thank Dr Moiseev¹ for his interest in our recent paper on the risk of venous thromboembolism (VTE) in patients with giant cell arteritis (GCA).² We agree that all systemic autoimmune rheumatic diseases (SARDs) are associated with an increased risk of VTE, as we and others have reported.^{3–6} Additionally, we have confirmed the increased risk of VTE in patients with GCA in another sample, and those results will be published soon.

We also agree with Dr Moiseev that the risk of VTE varies among SARDs. We have reported that patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis have a higher risk of VTE than those with GCA.⁷ It is likely that the interaction between the procoagulant state and each SARD may be different depending on the intrinsic pathogenesis of each disease.

It seems that Dr Moiseev is surprised that he did not see an increased risk of VTE in his small cohort of GCA cases; without knowing the characteristics of his cohort, we are unable to comment further on his findings. Dr Moiseev also inquired about cost-effective strategies to prevent VTE and raised concern about which patients should use preventive anticoagulation. In our paper, we proposed that preventative anticoagulation may be indicated only for those at high risk. Dr Moiseev asked who those patients that are at high risk are. This is a research question with no answer yet. We believe such investigation should be conducted urgently as it could result in the prevention of VTE.

In our study, we observed only one fatal event in the GCA cohort and nine in the non-GCA cohort. However, the low fatality rate observed does not contradict the use of preventative anticoagulation, given that VTE is associated with significant morbidity. Once we know who is at high risk, a randomised clinical trial should be implemented to test the hypothesis that preventable anticoagulation is cost effective. Until then, we agree that further research needs to be done to confirm our results, and to develop and test screening strategies to identify patients who may benefit from preventative anticoagulation.

J Antonio Aviña-Zubieta, V M Bhole, N Amiri, E C Sayre, H K Choi

Arthritis Research Centre of Canada, University of British Columbia, Vancouver, British Columbia, Canada

Correspondence to Dr J Antonio Aviña-Zubieta, Arthritis Research Centre of Canada, University of British Columbia, Vancouver, British Columbia V5Z 1L7, Canada; azubieta@arthritisresearch.ca

Competing interests None.

Provenance and peer review Commissioned; internally peer reviewed.

CrossMark

To cite Aviña-Zubieta JA, Bhole VM, Amiri N, *et al*. *Ann Rheum Dis* 2015;**74**:e28.

Received 30 October 2014

Accepted 3 November 2014

Published Online First 25 November 2014

► <http://dx.doi.org/10.1136/annrheumdis-2014-206849>

Ann Rheum Dis 2015;**74**:e28. doi:10.1136/annrheumdis-2014-206853

REFERENCES

- 1 Novikov P, Makarov E, Moiseev S, *et al*. Venous thromboembolic events in systemic vasculitis. *Ann Rheum Dis* 2015;**74**:e27.
- 2 Aviña-Zubieta JA, Bhole VM, Amiri N, *et al*. The risk of deep venous thrombosis and pulmonary embolism in giant cell arteritis: a general population-based study. *Ann Rheum Dis* 2014. Published Online First: 29 Sep 2014. doi:10.1136/annrheumdis-2014-205665
- 3 Carruthers EC, Choi HK, Sayre EC, *et al*. Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study. *Ann Rheum Dis* 2014.
- 4 Choi H, Rho Y, Zhu Y, *et al*. The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort study. *Ann Rheum Dis* 2013;**72**:1182–7.
- 5 Lee J, Pope J. A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases. *Arthritis Research & Therapy* 2014;**16**:435.
- 6 Zoller B, Li X, Sundquist J, *et al*. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. *Lancet* 2012;**379**:244–9.
- 7 Canadian Rheumatology Association Meeting Whistler, British Columbia, Canada 24 February to 1 March 2014. *J Rheumatol* 2014;**41**:1546 (Abstract).